MAR 16, 2016 10:30 AM PDT

Future of Psychopharmacology: Is New Treatment Innovation "Dead?"

Presented At Neuroscience
  • Adjunct Professor of Psychiatry, University of California, San Diego, Honorary Visiting Senior Fellow, University of Cambridge, UK, Chairman, Neuroscience Education Institute (NEI), Editor-in
      Dr. Stephen M. Stahl received his undergraduate and medical degrees from Northwestern University in Chicago, as a member of the honors program in Medical Education and his Ph.D. degree in pharmacology and physiology from the University of Chicago. Dr. Stahl has trained in three specialties: internal medicine at the University of Chicago; neurology at the University of California in San Francisco; and psychiatry at Stanford University. He is board certified in psychiatry.

      Dr. Stahl has held faculty positions at Stanford University, the University of California at Los Angeles, the Institute of Psychiatry London, the Institute of Neurology London, and, currently, as Adjunct Professor of Psychiatry at the University of California at San Diego. Dr. Stahl was also Executive Director of Clinical Neurosciences at the Merck Neuroscience Research Center in the UK for several years. Dr. Stahl's major interests are dedicated to producing and disseminating educational information about diseases and their treatments in psychiatry and neurology, with a special emphasis on multimedia, the internet and teaching how to teach.

      Dr. Stahl has conducted numerous research projects during his career awarded by the National Institute of Mental Health, by the Veterans Administration and by the pharmaceutical industry. Author of more than 350 articles and chapters, Dr. Stahl is an internationally recognized clinician, researcher and teacher in psychiatry with subspecialty expertise in psychopharmacology. Dr. Stahl has edited three books, and written four others, including the best-selling textbook, Essential Psychopharmacology, now in its third edition and the best selling clinical manual, Essential Psychopharmacology Prescriber's Guide.


    Innovation in Psychopharmacology is Dead. Long Live Innovation in Psychopharmacology!  
    What’s going on in our field? 

    • Priorities of Big Pharma shifting away from CNS and especially from psychiatry
    • Failed clinical trials littering the landscape
    • Even known drugs don’t work in psychiatric trials
    • Broken clinical trial apparatus
    • Iterative step-wise improvements or ‘me-too’ agents not reimbursed
    • Aggressive cost controls
    • No new validated targets

    Learning objectives - 

    • Discuss the reasons for the slow down of innovative new treatments entering psychopharmacology and the exit of Big Pharma largely from psychiatry
    • Show that future advances may be based on targeting symptoms that cut across a large array of psychiatric disorders
    • Propose that effective new treatments will be based upon subpopulations defined mostly in the short run by symptoms but in the long run by genetic and imaging biomarkers

    Show Resources
    Loading Comments...